A panel of medical experts discuss various categories of heart failure and their clinical implications.
This is a video synopsis/summary of a panel discussion involving Robert Groves, MD; Eugene E. Wright Jr, MD; Nancy Albert, PhD, CCNS, CCRN, CHFN, NE-BC, FAHA, FCCM, FHFSA, FAAN; Nihar Desai, MD, MPH; and Kelly Marie Axsom, MD. Axsom provides an overview of the current heart failure classification system, which categorizes patients based on ejection fraction (EF) and symptoms. Heart failure with preserved ejection fraction (HFpEF) has EF over 50% with elevated natriuretic peptides or signs of elevated filling pressures. Heart failure with reduced ejection fraction (HFrEF) has EF under 40%. There is also a midrange between 40% and 49% EF. Patients can move between categories over time. Even asymptomatic patients with only mildly reduced EF could be considered early-stage heart failure, where treatments could prevent progression. Albert emphasizes that once a patient has heart failure symptoms, they have the diagnosis even if symptoms later resolve. Heart failure is a chronic condition requiring lifelong treatment, as stopping treatment often leads to recurrence of worse symptoms within 2 years. Patients may feel their symptoms are stable, but it is important that they understand they have persistent heart failure that requires ongoing care. The updated classification system allows clearer categorization and more tailored management based on EF and symptom status.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More